This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AK-120, Famciclovir
Description: Famvir undergoes rapid biotransformation to the active antiviral compound penciclovir, which ahs inhibitory activity against cells infected with herpes simplex virus types 1 (HSV-1) or type 2 (HSV-2) or varicella zoster virus (VZV). In infected cells, viral thymidine kinase phosphorylates penciclovir to a monophosphate form that is converted to penciclovir triphosphate by cellular kinases. Penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and replication are selectively inhibited.
Novartis and Asahi Kasei
In January 2008, Novartis granted Asahi Kasei the right to distribute Famvir in Japan pursuant to a Restated Distribution Agreement.
Asahi Kasei and Maruho
In April 2008, Asahi Kasei entered into a marketing alliance with Maruho for famciclovir in the Japanese Market.
Partners: Asahi Kasei Corporation Maruho Co., Ltd.
Pink Sheet Fujisawa/SmithKline Beecham
Additional information available to subscribers only: